Furthermore, the interruption of GH replacement therapy in adults with childhood onset GHD may increase the risk of developing metabolic complications, including dyslipidemia and NAFLD, indirectly suggesting that long-term GH replacement therapy plays a role in preventing cardio-metabolic risk [166,167]. Here, GH1 is linked to metabolic dysfunction-associated steatotic liver disease.